Quillivant XR (methylphenidate HCl ext-rel; Pfizer) oral suspension and Quillichew ER (methylphenidate HCl ext-rel; Pfizer) chewable tablets are currently in shortage, according to the Food and Drug Administration (FDA).

Quillivant XR, a CNS stimulant, is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older. Due to a manufacturing delay, the following products are currently affected: bottles of 300mg powder (for 60mL suspension), bottles of 600mg powder (for 120mL suspension), bottles of 750mg powder (for 150mL suspension), and bottles of 900mg powder (for 180mL suspension). The next delivery and estimated recovery date is to be determined.

Quillichew ER, a CNS stimulant, is also indicated for the treatment of ADHD in patients aged 6 years and older. Due to a manufacturing delay, the 20mg tablets, 30mg tablets, and 40mg tablets in 100-count bottles are currently affected. The next delivery and estimated recovery date is to be determined. 

Related Articles

References

  1. FDA drug shortages: methylphenidate hydrochloride (QUILLICHEW ER) extended-release chewable tablets. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20(QUILLICHEW%20ER)%20Extended-Release%20Chewable%20Tablets&st=c. Updated January 22, 2018. Accessed January 25, 2018.
  2. FDA drug shortages: methylphenidate hydrochloride (QUILLIVANT XR) for extended-release oral suspension. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20(QUILLIVANT%20XR)%20for%20Extended-Release%20Oral%20Suspension&st=c. Updated January 22, 2018. Accesed January 25, 2018.

This article originally appeared on MPR